Featured Topics
Featured Products
Events
S&P Global Offerings
Featured Topics
Featured Products
Events
S&P Global Offerings
Featured Topics
Featured Products
Events
S&P Global Offerings
Featured Topics
Featured Products
Events
Financial and Market intelligence
Fundamental & Alternative Datasets
Government & Defense
Professional Services
Banking & Capital Markets
Economy & Finance
Energy Transition & Sustainability
Technology & Innovation
Podcasts & Newsletters
Financial and Market intelligence
Fundamental & Alternative Datasets
Government & Defense
Professional Services
Banking & Capital Markets
Economy & Finance
Energy Transition & Sustainability
Technology & Innovation
Podcasts & Newsletters
24 Feb, 2021
Investors today received allocations of Wedgewood Village Pharmacy Inc.'s $220 million seven-year covenant-lite term loan B that priced tight of talk via joint bookrunners Macquarie and Natixis, according to sources. Pricing was finalized at L+450 with a 0.75% Libor floor and an issue price of 99. The loan broke for trading in a 99.375/99.875 market, before ticking up to 99.625/100.125. The deal backs Partners Group's acquisition of Wedgewood from New Harbor Capital. Financing also includes a $40 million, five-year revolver with a springing first-lien leverage covenant.
Wedgewood Pharmacy provides compounded animal medications for acute and chronic conditions.
Terms:
| Borrower | Wedgewood Pharmacy |
| Issue | $220 million term loan B |
| UoP | LBO |
| Spread | L+450 |
| Libor floor | 0.75% |
| Price | 99 |
| Tenor | 7-year |
| YTM | 5.54% |
| Four-year yield | 5.65% |
| Call protection | 101 soft call for 6 months |
| Corporate ratings | B-/B3 |
| Facility ratings | B-/B3 |
| Recovery ratings | 3 |
| Financial covenants | None |
| Arrangers | Macq/Natx |
| Admin agent | Macq |
| Px Talk | L+475-500/0.75%/99 |
| Sponsor | Partners Group |
| Notes |